This trial is active, not recruiting.

Condition type 2 diabetes mellitus
Treatment pioglitazone/epa
Sponsor Albert Einstein College of Medicine of Yeshiva University
Collaborator Takeda
Trial identifier NCT00179400, 2000-200


Doctors are studying natural oils as potential therapies for type 2 diabetes. Animal studies have suggested promising results using EPA (found in fish oils) to improve insulin action and lower blood sugar levels.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification pharmacodynamics study
Intervention model single group assignment
Masking double-blind

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: Type 2 subjects with an A1c over 8.% Exclusion Criteria: Those with bleeding disorders including GERD, PUD, any GI bleeding; High blood pressure, and anyone with a history of Coronary Artery Disease or exertional chest pain

Additional Information

Official title The Role of Acute Combined Peroxisome Proliferator-Activated Receptors (PPAR) Alpha and Gamma Stimulation on Insulin Action in Humans
Principal investigator Meredith Hawkins, MD
Description PARTICIPATION INCLUDES: Participation in the studies includes taking study capsules for up to 21 days, keeping a meal diary, and up to four overnight hospital stays. During the hospital visits, an IV will be placed in each arm, and small amounts of muscle and fat tissue will be removed (with minimal discomfort). COMPENSATION: Compensation of $400 per study is provided (or up to $1,600 for completing all studies)
Trial information was received from ClinicalTrials.gov and was last updated in March 2012.
Information provided to ClinicalTrials.gov by Albert Einstein College of Medicine of Yeshiva University.